

Supplementary Table 1. Patient characteristics

Characteristic	Patients treated with cisplatin-doublet regime (n = 96)	Chemotherapy holiday (n = 9)
Age, yr	52 (30–70)	57 (34–65)
< 65	90 (93.8)	8 (88.9)
≥ 65	6 (6.2)	1 (11.1)
ECOG		
0–1	82 (85.4)	8 (88.9)
2	14 (14.6)	1 (11.1)
Hormone receptor status		
Positive	66 (68.8)	7 (77.8)
Negative	30 (31.2)	2 (22.2)
HER2 positive	17 (17.7)	3 (33.3)
Triple negative	21 (21.9)	1 (11.1)
Disease status		
Metastatic breast cancer	77 (80.2)	8 (88.9)
Recurrent breast cancer	19 (19.8)	1 (11.1)
Neoadjuvant chemotherapy		
Anthracycline	14 (14.6)	3 (33.3)
Taxane	7 (7.3)	2 (22.2)
Adjuvant chemotherapy		
Anthracycline	48 (50.0)	4 (44.4)
Taxane	22 (22.9)	1 (11.1)
Previous lines of palliative chemotherapy		
Naïve	7 (7.3)	1 (11.1)
1st	30 (31.3)	3 (33.3)
2nd	19 (19.7)	1 (11.1)
3rd	14 (14.6)	0
≥ 4th	26 (27.1)	4 (44.4)
Previous chemotherapy agents		
Gemcitabine	8 (8.3)	0
Vinorelbine	21 (21.9)	1 (11.1)
Eribulin	3 (3.1)	0
CMF	28 (29.2)	3 (33.3)
Capecitabine	22 (22.9)	8 (88.9)
Previous palliative endocrine treatment	36 (37.5)	6 (66.7)
Previous palliative HER2 treatment	13 (13.5)	2 (22.2)
No. of metastatic sites		
1	28 (29.2)	1 (11.1)
2	27 (28.1)	1 (11.1)
≥ 3	41 (42.7)	7 (77.8)
Metastatic sites		
Distant lymph nodes	39 (40.6)	5 (55.6)
Lung	40 (41.7)	5 (55.6)
Liver	29 (30.2)	1 (11.1)
Bone	45 (46.9)	6 (66.7)
Pleura	17 (17.7)	2 (22.2)
Brain	15 (15.6)	4 (44.4)
Visceral metastases	74 (77.1)	8 (88.9)

Values are presented as median (range) or number (%).

ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor 2; CMF, cyclophosphamide (oral) + methotrexate + 5-fluorouracil.